Kirk E Hevener

List of Publications by Year
in descending order

39 papers	1,687 citations	430442 18 h-index	315357 38 g-index
39 all docs	39 docs citations	39 times ranked	2872 citing authors

#	Article	IF	Citations
1	Concise Synthesis of Tunicamycinâ€…V and Discovery of a Cytostatic DPAGT1 Inhibitor. Angewandte Chemie - International Edition, 2022, 61, .	7.2	7
2	Antibacterial kaneoheoic acids A-F from a Hawaiian fungus Fusarium sp. FM701. Phytochemistry, 2021, 181, 112545.	1.4	9
3	The Discovery and Development of Thienopyrimidines as Inhibitors of Helicobacter pylori That Act through Inhibition of the Respiratory Complex I. ACS Infectious Diseases, 2021, 7, 1044-1058.	1.8	6
4	Identification of Dual-Target Compounds with Antifungal and Anti-NLRP3 Inflammasome Activity. ACS Infectious Diseases, 2021, 7, 2522-2535.	1.8	2
5	Constitutive expression of the cryptic vanGCd operon promotes vancomycin resistance in Clostridioides difficile clinical isolates. Journal of Antimicrobial Chemotherapy, 2020, 75, 859-867.	1.3	39
6	Second-Generation Antidiabetic Sulfonylureas Inhibit Candida albicans and Candidalysin-Mediated Activation of the NLRP3 Inflammasome. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	20
7	DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors. Journal of Medicinal Chemistry, 2020, 63, 10855-10878.	2.9	10
8	Crystal structure of the 65-kilodalton amino-terminal fragment of DNA topoisomerase I from the gram-positive model organism Streptococcus mutans. Biochemical and Biophysical Research Communications, 2019, 516, 333-338.	1.0	5
9	Identification of Small Molecules Exhibiting Oxacillin Synergy through a Novel Assay for Inhibition of vraTSR Expression in Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	10
10	Small-Molecule Inhibition of the C. difficile FAS-II Enzyme, FabK, Results in Selective Activity. ACS Chemical Biology, 2019, 14, 1528-1535.	1.6	8
11	The Vacuolar Ca ²⁺ ATPase Pump Pmc1p Is Required for Candida albicans Pathogenesis. MSphere, 2019, 4, .	1.3	14
12	The Fatty Acid Synthesis Protein Enoyl-ACP Reductase II (FabK) is a Target for Narrow-Spectrum Antibacterials for Clostridium difficile Infection. ACS Infectious Diseases, 2019, 5, 208-217.	1.8	30
13	Pharmacophore Modeling, Synthesis, and Antibacterial Evaluation of Chalcones and Derivatives. ACS Omega, 2018, 3, 18343-18360.	1.6	20
14	Hit-to-Lead: Hit Validation and Assessment. Methods in Enzymology, 2018, 610, 265-309.	0.4	23
15	Recent developments in topoisomerase-targeted cancer chemotherapy. Acta Pharmaceutica Sinica B, 2018, 8, 844-861.	5.7	166
16	Structural characterization ofPorphyromonas gingivalisenoyl-ACP reductase II (FabK). Acta Crystallographica Section F, Structural Biology Communications, 2018, 74, 105-112.	0.4	11
17	Computational Toxicology Methods in Chemical Library Design and High-Throughput Screening Hit Validation. Methods in Molecular Biology, 2018, 1800, 275-285.	0.4	18
18	Recent advances in the rational design and optimization of antibacterial agents. MedChemComm, 2016, 7, 1694-1715.	3.5	19

#	Article	IF	Citations
19	Rifamycin Resistance in Clostridium difficile Is Generally Associated with a Low Fitness Burden. Antimicrobial Agents and Chemotherapy, 2016, 60, 5604-5607.	1.4	16
20	A simplified protocol for high-yield expression and purification of bacterial topoisomerase I. Protein Expression and Purification, 2016, 124, 32-40.	0.6	2
21	Comparison of radii sets, entropy, <scp>QM</scp> methods, and sampling on <scp>MMâ€PBSA</scp>, <scp>MMâ€GBSA</scp>, and <scp>QM/MMâ€GBSA</scp> ligand binding energies of <scp>F</scp>. tularensis enoylâ€<scp>ACP</scp> reductase (<scp>F</scp>abI). Journal of Computational Chemistry, 2015, 36, 1859-1873.	1.5	91
22	Structural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI). Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1292-1296.	1.0	18
23	Special Challenges to the Rational Design of Antibacterial Agents. Annual Reports in Medicinal Chemistry, 2013, 48, 283-298.	0.5	6
24	Fragment-Based Drug Discovery Using a Multidomain, Parallel MD-MM/PBSA Screening Protocol. Journal of Chemical Information and Modeling, 2013, 53, 560-572.	2.5	18
25	Hit Identification and Optimization in Virtual Screening: Practical Recommendations Based on a Critical Literature Analysis. Journal of Medicinal Chemistry, 2013, 56, 6560-6572.	2.9	215
26	High-level expression, purification, and characterization of Staphylococcus aureus dihydroorotase (PyrC) as a cleavable His-SUMO fusion. Protein Expression and Purification, 2013, 88, 98-106.	0.6	16
27	Synergistic Inhibitor Binding to the Papainâ€Like Protease of Human SARS Coronavirus: Mechanistic and Inhibitor Design Implications. ChemMedChem, 2013, 8, 1361-1372.	1.6	19
28	High-Throughput Screening (HTS) and Hit Validation to Identify Small Molecule Inhibitors with Activity against NS3/4A proteases from Multiple Hepatitis C Virus Genotypes. PLoS ONE, 2013, 8, e75144.	1.1	21
29	Discovery of a Novel and Potent Class of F. tularensis Enoyl-Reductase (FabI) Inhibitors by Molecular Shape and Electrostatic Matching. Journal of Medicinal Chemistry, 2012, 55, 268-279.	2.9	57
30	Expression, purification and characterization of enoyl-ACP reductase II, FabK, from Porphyromonas gingivalis. Protein Expression and Purification, 2012, 85, 100-108.	0.6	5
31	Structural and Enzymatic Analyses Reveal the Binding Mode of a Novel Series of Francisella tularensis Enoyl Reductase (FabI) Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 5933-5941.	2.9	20
32	Structural Studies of Pterin-Based Inhibitors of Dihydropteroate Synthase. Journal of Medicinal Chemistry, 2010, 53, 166-177.	2.9	81
33	A statistical framework to evaluate virtual screening. BMC Bioinformatics, 2009, 10, 225.	1.2	81
34	Validation of Molecular Docking Programs for Virtual Screening against Dihydropteroate Synthase. Journal of Chemical Information and Modeling, 2009, 49, 444-460.	2.5	367
35	Quantitative structureâ€“activity relationship studies on nitrofuranyl anti-tubercular agents. Bioorganic and Medicinal Chemistry, 2008, 16, 8042-8053.	1.4	46
36	Structureâ€“activity relationships and enzyme inhibition of pantothenamide-type pantothenate kinase inhibitors. Bioorganic and Medicinal Chemistry, 2006, 14, 1007-1020.	1.4	61

#	Article	IF	Citations
37	The Structure of the Pantothenate KinaseÂ·ADPÂ·Pantothenate Ternary Complex Reveals the Relationship between the Binding Sites for Substrate, Allosteric Regulator, and Antimetabolites. Journal of Biological Chemistry, 2004, 279, 35622-35629.	1.6	47
38	Synthesis and Evaluation of Nitrofuranylamides as Novel Antituberculosis Agents. Journal of Medicinal Chemistry, 2004, 47, 5276-5283.	2.9	81
39	Concise Synthesis of Tunicamycin V and Discovery of a Cytostatic DPAGT1 Inhibitor. Angewandte Chemie, 0, , .	1.6	2